240 related articles for article (PubMed ID: 23763896)
21. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
22. Healthcare professionals and pharmacovigilance of pediatric adverse drug reactions: a 5-year analysis of Adverse Events Reporting System Database of the Food and Drug Administration.
Bigi C; Tuccori M; Bocci G
Minerva Pediatr (Torino); 2022 Jun; 74(3):272-280. PubMed ID: 28211644
[TBL] [Abstract][Full Text] [Related]
23. Paradoxical adverse drug reactions: descriptive analysis of French reports.
Hakimi Y; Petitpain N; Pinzani V; Montastruc JL; Bagheri H
Eur J Clin Pharmacol; 2020 Aug; 76(8):1169-1174. PubMed ID: 32418024
[TBL] [Abstract][Full Text] [Related]
24. [Knowledge creation about adverse drug reactions in the paediatric population].
Aagaard L
Ugeskr Laeger; 2013 Feb; 175(6):342-5. PubMed ID: 23402239
[TBL] [Abstract][Full Text] [Related]
25. Bulgarian Experience with Adverse Drug Reaction Reports from Patients and Consumers - Retrospective Data-base Study.
Getova VI; Georgiev SR; Stoimenova AH; Petkova-Georgieva ES
Folia Med (Plovdiv); 2018 Sep; 60(3):447-453. PubMed ID: 30355838
[TBL] [Abstract][Full Text] [Related]
26. Side effects reported by European consumers for medications for erectile dysfunction.
Aagaard L; Hansen EH
J Res Pharm Pract; 2013 Apr; 2(2):93-5. PubMed ID: 24991611
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of completeness of suspected adverse drug reaction reports submitted to the mexican national pharmacovigilance centre: a cross-sectional period-prevalence study.
Sánchez-Sánchez B; Altagracia-Martínez M; Kravzov-Jinich J; Moreno-Bonett C; Vázquez-Moreno E; Martínez-Núñez JM
Drug Saf; 2012 Oct; 35(10):837-44. PubMed ID: 22924896
[TBL] [Abstract][Full Text] [Related]
28. The temporal association between adverse drug reactions and antirheumatic drugs utilisation in Western Australia: a retrospective study from real-world data (1995-2015).
Almutairi KB; Inderjeeth CA; Preen DB; Keen HI; Nossent JC
Rheumatol Int; 2024 Jun; 44(6):1089-1099. PubMed ID: 38615313
[TBL] [Abstract][Full Text] [Related]
29. A Retrospective Analysis of Spontaneous Adverse Drug Reactions Reports Relating to Paediatric Patients.
Rosli R; Ming LC; Abd Aziz N; Manan MM
PLoS One; 2016; 11(6):e0155385. PubMed ID: 27249414
[TBL] [Abstract][Full Text] [Related]
30. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
[TBL] [Abstract][Full Text] [Related]
31. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
[TBL] [Abstract][Full Text] [Related]
32. Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.
Matos C; van Hunsel F; Joaquim J
Eur J Clin Pharmacol; 2015 Jul; 71(7):883-90. PubMed ID: 26004569
[TBL] [Abstract][Full Text] [Related]
33. What can we learn from consumer reports on psychiatric adverse drug reactions with antidepressant medication? Experiences from reports to a consumer association.
Vilhelmsson A; Svensson T; Meeuwisse A; Carlsten A
BMC Clin Pharmacol; 2011 Oct; 11():16. PubMed ID: 22026961
[TBL] [Abstract][Full Text] [Related]
34. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
Svendsen K; Wood M; Olsson E; Nordeng H
Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
[TBL] [Abstract][Full Text] [Related]
35. Adverse drug reactions in Colombian patients, 2007-2013: Analysis of population databases.
Machado-Alba JE; Londoño-Builes MJ; Echeverri-Cataño LF; Ochoa-Orozco SA
Biomedica; 2016 Mar; 36(1):59-66. PubMed ID: 27622439
[TBL] [Abstract][Full Text] [Related]
36. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001).
Thiessard F; Roux E; Miremont-Salamé G; Fourrier-Réglat A; Haramburu F; Tubert-Bitter P; Bégaud B
Drug Saf; 2005; 28(8):731-40. PubMed ID: 16048358
[TBL] [Abstract][Full Text] [Related]
37. Analysis of Reporting Adverse Drug Reactions in Paediatric Patients in a University Hospital in the Netherlands.
Dittrich ATM; Draaisma JMT; van Puijenbroek EP; Loo DMWMT
Paediatr Drugs; 2020 Aug; 22(4):425-432. PubMed ID: 32557243
[TBL] [Abstract][Full Text] [Related]
38. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
39. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
[TBL] [Abstract][Full Text] [Related]
40. Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports.
Leitzen S; Dubrall D; Toni I; Stingl J; Christ P; Köberle U; Schmid M; Neubert A; Sachs B
Paediatr Drugs; 2023 Mar; 25(2):203-215. PubMed ID: 36369590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
